Chief Physician, Level 2 Professor, Doctoral Supervisor, Director of Shanghai Institute of Hematology, Vice President of Ruijin Hospital
Affiliated HospitalRuijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
→
-Research areas : lymphoma immunotherapy, CAR-T cell therapy clinical research, and real-world CAR-T studies in Asian populations.
- Cutting-edge technologies: CAR-T stratified treatment system for relapsed and refractory large B-cell lymphoma; CAR-T adverse reaction MDT management model.
- Areas of expertise: Diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, and other B-cell non-Hodgkin lymphomas.
- Academic Highlights: Led a multicenter real-world study of CAR-T therapy for lymphoma in China; published clinical evidence of CAR-T in Asian populations in NEJM; recipient of the Wu Jieping Medical Innovation Award; Standing Committee Member of the Hematology Branch of the Chinese Medical Association.
- Core Value: To establish a standardized CAR-T treatment system suitable for Chinese lymphoma patients and to promote domestically produced CAR-T clinical data to the international community.